Kemia, Inc. Announces Completion Of Phase I Trials For Oral Anti-Inflammatory Drug; KC706, A p38 MAP Kinase Inhibitor, Targets Inflammatory Conditions Including Arthritis, Psoriasis, And Cardiovascular Disease
Published: Aug 23, 2006
SAN DIEGO--(BUSINESS WIRE)--Aug. 23, 2006--Kemia announced today that the company has completed initial Phase I clinical trials with KC706, a novel oral anti-inflammatory drug that works by selectively and allosterically inhibiting p38 MAP kinase. Based on these successful Phase I trials, Kemia now plans to evaluate KC706 in several diseases characterized by chronic inflammation. The first Phase IIa clinical trial, treating patients suffering from rheumatoid arthritis, will commence at the end of September.